Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy

Dr Thierry Andre - Sorbonne Université and Saint Antoine Hospital, Paris, France
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy ( Dr Thierry Andre - Sorbonne Université and Saint Antoine Hospital, Paris, France )
13 Feb 2025

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs

Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs ( Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan )
29 Jan 2025

Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients

Dr Efrat Dotan - University of Pennsylvania, Philadelphia, USA
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients ( Dr Efrat Dotan - University of Pennsylvania, Philadelphia, USA )
24 Jan 2025

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )
14 Jan 2025

Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma

Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma ( Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA )
13 Jan 2025

The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America

Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala
The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America ( Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala )
13 Jan 2025

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results

Prof Salomon Manier - Hospital Center University De Lille, Lille, France
Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )
9 Jan 2025

SABCS 2024: Highlights in breast cancer genomic testing

Prof Matteo Lambertini and Prof Virginia Kaklamani
SABCS 2024: Highlights in breast cancer genomic testing ( Prof Matteo Lambertini and Prof Virginia Kaklamani )
23 Dec 2024

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL

Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA
Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL ( Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA )
20 Dec 2024

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Dr Nan Chen - The University of Chicago, Chicago, USA
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC ( Dr Nan Chen - The University of Chicago, Chicago, USA )
19 Dec 2024

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK
Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )
19 Dec 2024

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
19 Dec 2024